TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancersEleonora Ghisoni(University Hospital of Lausanne), Giorgio Valabrega(CTO Hospital)Journal of Ovarian ResearchFebruary 13, 201910.1186/s13048-019-0492-6Cited by 33SaveCiteExport RISWatch citationsRelated PapersXenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer|Oncotarget|2016|16